Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 10.00 GBp
Change Today 0.00 / 0.00%
Volume 110.0K
LID On Other Exchanges
As of 12:30 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

lidco group plc (LID) Snapshot

10.00 GBp
Previous Close
10.00 GBp
Day High
10.00 GBp
Day Low
10.00 GBp
52 Week High
04/10/14 - 24.50 GBp
52 Week Low
02/11/15 - 5.38 GBp
Market Cap
Average Volume 10 Days
0.0008 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for LIDCO GROUP PLC (LID)

Related News

No related news articles were found.

lidco group plc (LID) Related Businessweek News

No Related Businessweek News Found

lidco group plc (LID) Details

LiDCO Group Plc develops, manufactures, and sells cardiac monitoring equipment in the United Kingdom, the United States, Continental Europe, Japan, and internationally. It offers LiDCOplus, a computer-based platform monitor, which is used in the intensive care unit for real-time continuous display of hemodynamic parameters, such as cardiac output, oxygen delivery, and fluid-volume responsiveness; and LiDCOrapid, a cardiac output monitor for use in the operating theatre for fluid and drug management. The company also provides LiDCOview, an easy-to-use graphical display of historical data that is used for research and education purposes; and LiDCOrapidv2 with Unity software, which is designed for multi-parameter monitoring of anesthesia and fluids. It sells its products through direct sales and a network of distributors. The company was founded in 1991 and is headquartered in London, the United Kingdom.

50 Employees
Last Reported Date: 04/29/14
Founded in 1991

lidco group plc (LID) Top Compensated Officers

Co-Founder, Chief Executive Officer, Executiv...
Total Annual Compensation: 253.0K GBP
Co-Founder and Member of Clinical Advisory Bo...
Total Annual Compensation: --
Finance Director and Executive Director
Total Annual Compensation: 194.0K GBP
Compensation as of Fiscal Year 2014.

lidco group plc (LID) Key Developments

LiDCO Group Plc Showcases Portable LiDCO Stand System at ISICEM Brussels

LiDCO Group Plc announced that the company will be attending the International Symposium on Intensive Care and Emergency Medicine ('ISICEM') and will be showcasing its new portable LiDCO Battery Monitor Stand System ('BMSS') for the first time. LiDCO will be showcasing the company's products along with its new portable LiDCO BMSS at stand 1.07 -1.08 throughout the trade show which is being held on 17 March 2015 through till 20 March 2015. The portability of LiDCO's BMSS when combined with the existing non-invasive functionality creates many benefits for users of LiDCO's technology. The LiDCOrapid monitor can now be used mains free on battery power for up to six hours allowing it to be moved to different locations in the hospital where mains power might not be easily available. It can be used in pre-anaesthesia rooms to monitor fluid and drug requirements after anaesthetic induction and then keep continuously monitoring the patient as they are moved to the operating room. It can accompany the patient from the operating room to the post-operative recovery or intensive care ward, allowing practitioners a continuous hemodynamic monitoring record of both the surgery and recovery periods on a single monitor. It also allows it to be used within A&E as it can be more easily moved to assess and screen shock patients potentially requiring fluid resuscitation. The LiDCO BMSS received the certification required by the medical standard IEC 60601-1 (a series of technical standards for the safety and effectiveness of medical electrical equipment) on 13 March 2015. The development of the BMSS will allow LiDCO access to even more patients that need real-time hemodynamic monitoring, helping to reduce morbidity and complications, length of stay in hospital and overall costs associated with major surgery.

LiDCO Group plc Provides Earnings Guidance for the Year Ended January 31, 2015; Announces Sales Results for the Year Ended January 31, 2015

LiDCO Group plc provided earnings guidance for the year ended January 31, 2015. For the period, the company expected to record revenues of £8.27 million and pre-tax profits (adjusted for share based payments) to be broadly in line with market expectations, being at a similar level to the year ended 31 January 2014. Despite a reduction in revenues from an exceptionally strong 2014 performance, the company has maintained profitability through improved gross margins and tight control of overheads. The company also reported that its product sales (excluding third party products) were down slightly at £6.63 million in fiscal 2015 compared to £6.87 million in fiscal 2014, overall sales of high margin surgical disposables increased by 5% to £3.23 million compared to £3.08 million a year ago. International sales were up 8.5% to £2.67 million compared to £2.46 million in 2014, including a significant uplift of 29% in the US and 76% in ROW (excluding Japan). The performance in Japan continues to be disappointing and the Company is reviewing its exclusive distribution arrangements whilst making good progress in registering the non-invasive product.

LiDCO Group plc Announces Publication of British Journal of Surgery

LiDCO Group Plc announced that it welcomes the publication in the British Journal of Surgery of a paper on behalf of the ELPQuiC Collaborator Group, entitled "Use of a pathway quality improvement care bundle to reduce mortality after emergency laparotomy." The study concludes that the implementation of an evidence-based care bundle for patients undergoing emergency laparotomy was associated with a significant reduction in the risk of death following the surgery. The emergency laparotomy pathway quality improvement care (ELPQuiC) bundle included goal-directed fluid therapy provided throughout the study using the LiDCOrapid cardiac output monitor both during surgery and for 6 hours while the patient was cared for in the intensive care unit. An initial assessment with an early warning score assessed on presentation; Early administration of antibiotics; An interval between decision and operation of less than 6 hours; Goal-directed fluid therapy using cardiac output monitoring (via LiDCOrapid); Postoperative intensive care. The study, which was conducted in four NHS hospitals, showed that the number of lives saved per 100 patients treated rose from 6.47 to 12.44 and the overall adjusted risk of 30-day mortality significantly decreased from 15.6% to 9.6%. The study's authors concluded that 5.97 more lives saved per 100 patients treated overall compared with outcomes before implementation of the ELPQuiC bundle. Approximately 50,000 emergency laparotomies are carried out in the UK each year and on average 15% of these patients will die within 30 days of the surgery. This group of patients are one of the higher risk hospital patient populations. All hospitals in England and Wales are required to submit outcome data on these patients to the National Emergency Laparotomy Audit. This study has shown that implementing an evidence-based care bundle improved the quality of care to achieve a significant reduction in risk-adjusted mortality after emergency laparotomy. The ELPQuiC Collaborator Group was formed from four acute Trusts in England, comprising of the Royal Surrey County Hospital NHS Foundation Trust, Guildford; the Royal United Hospital Bath NHS Trust, Bath; the South Devon Healthcare NHS Foundation Trust, Torbay Hospital, Torbay; and the Royal Devon and Exeter NHS Foundation Trust, Exeter.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LID:LN 10.00 GBp 0.00

LID Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Deltex Medical Group PLC 4.38 GBp +0.25
Edwards Lifesciences Corp $143.68 USD +1.78
ICU Medical Inc $92.27 USD +1.29
Masimo Corp $31.84 USD +0.42
Pulsion Medical Systems SE €24.45 EUR 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation LID Industry Range
Price/Earnings 100.0x
Price/Sales 2.1x
Price/Book 2.4x
Price/Cash Flow 101.8x
TEV/Sales 2.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIDCO GROUP PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at